PDCD1 and melanoma: Blockade of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has been shown to elicit durable T cell-dependent antitumor responses in melanoma patients and a preclinical model of melanoma (B16 melanoma-bearing mice)27,28.